Quality and fragility of meta-analyses assessing the efficacy and safety of Ginkgo biloba preparation: protocol for a methodological study.

Abstract

Ginkgo biloba L. (GB) is an ancient plant with high medicinal value. GB preparations are widely used to treat diseases such as angina pectoris, ischemic stroke, and dementia. Many meta-analyses of GB preparations for these diseases have recently been published. However, the methodological and reporting quality of relevant meta-analyses have not been systematically evaluated and reported to date. Therefore, the present methodological study was designed to fill this knowledge gap. PubMed, Embase, CNKI, WanFang, and the Chinese Biomedical Literature Database will be comprehensively searched from inception to June 2022. Meta-analyses on the efficacy and safety of GB preparations for humans with health conditions will be included. Two researchers will independently screen the literature, extract the data, and evaluate the methodological and reporting quality through AMSTAR-2 and PRISMA 2020. Spearman correlation coefficient will be used to evaluate the correlation between methodological and reporting quality. Five factors potentially affecting the methodological quality will be evaluated through univariate and multivariate linear analyses. The fragility index of statistically significant binary outcomes will be calculated to assess the robustness of pooled results. Stata 16.0 and Excel 2016 will be utilized to conduct the statistical analysis, and P<0.05 will be considered statistically significant. This is the first research to thoroughly investigate the methodological and reporting quality of GB preparations for health conditions. The results of this investigation will improve the quality of future studies and clinical decision-making.